[company_age]5.0[/company_age][employees]2-10 employees[/employees][funding]Series unknown[/funding][description]Pacertool is a medical device company that develops a proprietary technology platform called PaCRTool-System. This system is designed to improve cardiac resynchronization therapy (CRT) in heart failure patients by providing healthcare professionals with quantifiable evidence to determine when CRT is effectively applied and ensure synergy from biventricular pacing. The company's technology addresses two major unmet needs in pacing for heart failure patients: patient selection and verified lead placement. Pacertool is focused on the US market and is implementing a 510(k) strategy in parallel with early safety and feasibility clinical data. \n\nWhat makes Pacertool unique is its focus on developing a technology that can quantify the heart's resynchronization potential in real-time during pacemaker implantation. This is achieved through the use of a proprietary electromechanical biomarker that can be measured with the PreSens-Catheter. This biomarker indicates whether the heart can be resynchronized with a pacemaker and can be used to optimize treatment. \n\nThe global CRT market size is expected to reach USD 7 Billion by 2028, growing at a CAGR of 5.5% during 2023-2028. Pacertool is well-positioned to capitalize on this growing market with its innovative technology and focus on the US market.[/description][ps]PaCRTool-System, PreSens-Catheter[/ps]